Date: 2016-12-12
Type of information: Resignation
Compound:
Company: Ipsen (France)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On December 12, 2016, Ipsen announced that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will depart Ipsen on January 2nd, 2017, to join another company. Pending Claude Bertrand’s replacement,Alexandre Lebeaut, MD, will lead the R&D division in the interim. Dr. Lebeaut, Senior Vice President, Global Drug Development joined Ipsen in 2012, bringing a long and solid medical and managerial experience after having spent more than 20 years in large pharmaceutical and biotechnology companies, with extensive international experience in Italy, France, and mostly North America.
Financial terms:
Latest news:
